PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS
Yu Yao(Qinghai University), Nancy Ann Oberheim Bush(University of California, San Francisco), Joanna J. Phillips(University of California, San Francisco), Annette M. Molinaro(University of California, San Francisco), Javier Villanueva‐Meyer(Baylor College of Medicine), Jennifer Clarke(Cornell University), Stephanie Hilz(University of California, San Francisco), Michael Wahl(Regional Cancer Center), Anny Shai(University of California, San Francisco), Matthew Grimmer(Sequenom (United States)), Jennie Taylor(University of California, San Francisco), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), David A. Solomon(University of California, San Francisco), J Costello(University of California, San Francisco), Nicholas Butowski(University of California, San Francisco), Michael McDermott(University of California, San Francisco), Susan M. Chang(University of California, San Francisco), Serah Choi(University of Pittsburgh Medical Center), Tali Mazor(Dana-Farber Cancer Institute), Chibo Hong(Universidad Católica de Santa Fe), Mitchel S. Berger(University of California, San Francisco)
Cited by 0
Related Papers
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
|Archives of General Psychiatry|2002|2.1k
The NIH Roadmap Epigenomics Mapping Consortium
|Nature Biotechnology|2010|2k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k